Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.

Tomacinschii Victor; Robu Maria; Corcimaru Ion; Musteaţă Vasile; Musteaţă Larisa; Buruiana Sanda; Sporîș Natalia; Popescu Maria

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

990

Ultima descărcare din IBN:
2023-12-01 16:44

Căutarea după subiecte
similare conform CZU

616.155.392-07-036.1-08 (1)

Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (975)

SM ISO690:2012

TOMACINSCHII, Victor, ROBU, Maria, CORCIMARU, Ion, MUSTEAŢĂ, Vasile, MUSTEAŢĂ, Larisa, BURUIANA, Sanda, SPORÎȘ, Natalia , POPESCU, Maria. Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2018, nr. 2-3(59-60), pp. 61-65. ISSN 1857-0011.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale

Numărul 2-3(59-60) / 2018 / ISSN 1857-0011

Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.

Clinical aspects and treatment outcomes of chronic lymphocytic leukemia.

Клинические аспекты и результаты лечения хронического лимфолейкоза.

CZU: 616.155.392-07-036.1-08

Pag. 61-65

Tomacinschii Victor¹, Robu Maria¹, Corcimaru Ion¹, Musteaţă Vasile¹², Musteaţă Larisa¹, Buruiana Sanda¹², Sporîș Natalia ²¹, Popescu Maria¹²

¹ Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“,
² IMSP Institutul Oncologic

Disponibil în IBN: 4 ianuarie 2019

Descarcă PDF

Rezumat

Au fost analizate particularitaţile evoluţiei clinice, prognostice și rezultatele nemijlocite ale tratamentului pe un lot de 118 pacienţi cu leucemie limfocitară cronică. Leucemia limfocitară cronică mai frecvent s-a dezvoltat la persoane cu vârsta 55-75 ani(69,4%), aproximativ cu aceeași frecvență la bărbați și femei(51% și 49% respectiv). S-a dovedit, că tratamentul cu utilizarea regimurilor terapeutice noi crește rata răspunsului la tratament și îmbunătăţeşte calitatea vieţii pacienţilor.

The peculiarities of clinical evolution, prognosis and immediate treatment outcomes were analyzed in a group of 118 patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia more frequently developed in patients aged between 55-75 years (69.4%), approximately with the same frequency in males and females (51% and 49%, respectively). It has been shown that treatment with new therapeutic regimens improves the rate of response to treatment and patients quality of life.

Изучены особенности клинического течения, непосредственные результаты лечения и прогноз у 118 пациентов с хроническим лимфолейкозом. Заболевание чаще (69,4%) диагностировали у лиц в возрасте от 55 до 75 лет примерно с одинаковой частотой у мужчин и женщин (51% и 49%, соответственно). Лечение современными химиотерапевтическими режимами увеличивает частоту ремиссий и улучшает качество жизни пациентов.

Cuvinte-cheie
leucemie limfocitară cronică, evoluție clinică, prognostic, tratament.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-70211</cfResPublId>
<cfResPublDate>2018-12-25</cfResPublDate>
<cfVol>59-60</cfVol>
<cfIssue>2-3</cfIssue>
<cfStartPage>61</cfStartPage>
<cfISSN>1857-0011</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/70211</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice.</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>leucemie limfocitară cronică; evoluție clinică; prognostic; tratament.</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Au fost analizate particularitaţile evoluţiei clinice, prognostice și rezultatele nemijlocite ale tratamentului pe un lot de 118 pacienţi cu leucemie limfocitară cronică. Leucemia limfocitară cronică mai frecvent s-a dezvoltat la persoane cu v&acirc;rsta 55-75 ani(69,4%), aproximativ cu aceeași frecvență la bărbați și femei(51% și 49% respectiv). S-a dovedit, că tratamentul cu utilizarea regimurilor terapeutice noi crește rata răspunsului la tratament și &icirc;mbunătăţeşte calitatea vieţii pacienţilor.</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The peculiarities of clinical evolution, prognosis and immediate treatment outcomes were analyzed in a group of 118 patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia more frequently developed in patients aged between 55-75 years (69.4%), approximately with the same frequency in males and females (51% and 49%, respectively). It has been shown that treatment with new therapeutic regimens improves the rate of response to treatment and patients quality of life.</p></cfAbstr>
<cfAbstr cfLangCode='RU' cfTrans='o'><p>Изучены особенности клинического течения, непосредственные результаты лечения и прогноз у 118 пациентов с хроническим лимфолейкозом. Заболевание чаще (69,4%) диагностировали у лиц в возрасте от 55 до 75 лет примерно с одинаковой частотой у мужчин и женщин (51% и 49%, соответственно). Лечение современными химиотерапевтическими режимами увеличивает частоту ремиссий и улучшает качество жизни пациентов.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-60743</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11551</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11697</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11430</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11429</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-17453</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-104126</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29191</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-60743</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-60743-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Tomacinschii</cfFamilyNames>
<cfFirstNames>Victor</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11551</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11551-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Robu</cfFamilyNames>
<cfFirstNames>Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11697</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11697-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Корчмару</cfFamilyNames>
<cfFirstNames>Ион</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11430</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11430-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Musteaţă</cfFamilyNames>
<cfFirstNames>Vasile</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11429</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11429-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Musteaţă</cfFamilyNames>
<cfFirstNames>Larisa</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-17453</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-17453-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Buruiana</cfFamilyNames>
<cfFirstNames>Sanda</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-104126</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-104126-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Sporîș</cfFamilyNames>
<cfFirstNames>Natalia </cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29191</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29191-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2018-12-25T24:00:00</cfStartDate>
<cfFamilyNames>Popescu</cfFamilyNames>
<cfFirstNames>Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>